For US Healthcare Professionals only.
*In vitro activity does not necessarily correlate with clinical efficacy.
†Study description
The activity of meropenem in combination with vaborbactam against >1900 KPC-producing clinical
isolates of Enterobacterales was evaluated in both prospective and retrospective in vitro studies.
Vaborbactam potentiated the activity of meropenem in these studies; lowest concentrations of the
antibiotic at which 90% of the isolates were inhibited (MIC90s) were >32 μg/mL for
meropenem alone and were reduced to 0.5-
*In vitro activity does not necessarily correlate with clinical efficacy.
Study description
A total of 14,304 gram-negative bacterial clinical isolates were consecutively collected in 82 worldwide hospitals. All isolates were tested for susceptibility against meropenem-vaborbactam and comparators using the reference broth microdilution method as described by the Clinical and Laboratory Standards Institute (CLSI). Meropenem was combined with vaborbactam at a fixed concentration of 8μg/mL.2
The efficacy of VABOMERE in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials, and in vitro data does not necessarily correlate to clinical efficacy.
References: 1. Data on file: Melinta Therapeutics, LLC. 2. Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454-5458. 3. Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem. 2015;58(9):3682-3692.
4. VABOMERE [package insert]: Melinta Therapeutics, LLC. 5. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68(6):803-838. 6. Bhowmick T, Weinstein MP. Microbiology of meropenem-vaborbactam: a novel carbapenem beta-lactamase inhibitor combination for carbapenem-resistant Enterobacterales infections. Infect Dis Ther. 2020;9(4):757-767.
VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.
Please see full Prescribing Information.
Distribution Change for AmerisourceBergen, Cardinal, and McKesson – Now Order Exclusively through Specialty Distribution |
x
|